Fero Industries to Acquire Pyro Pharmaceuticals, Inc.'s Enzyme Identification Methodology under Definitive Agreement.

Pyro Methodology Holds the Potential to Attack Antibiotic Resistant Bacteria

CALGARY, Alberta -- Fero Industries, Inc. (OTCBB: FROI) (the "Company") is pleased to announce that it is acquiring Pyro Pharmaceuticals, Inc.'s patented enzyme identification methodology through its pending acquisition of Pyro Pharmaceuticals. As previously announced, Fero has initiated the process of acquiring Pyro Pharmaceuticals, Inc. through an exchange of Pyro's capital stock for shares of the Company's common stock, with Fero remaining as the parent entity and Pyro as a subsidiary. The acquisition of Pyro is expected to close by November 30, 2009.

Alan M. Schechter, Chairman and CEO, stated, "Pyro's enzyme identification methodology has the potential to provide a new and promising way of identifying bacterial enzymes that are used as targets for antibiotic therapy and combating multi-drug resistant infectious microorganisms. We had developed a patent portfolio with an issued patent, United States Patent No. 6955890, and several pending patents."

Mr. Schechter continued, "Pyro's patented method identifies enzymes involved in essential metabolic pathways that could be the subject of antimicrobial targets. Blocking a metabolic pathway by inhibiting one or more enzymes in a pathway can form the basis for an inborn error in metabolism, or death to the microorganism, or in this case antibiotic resistant bacteria, incapable of inducing disease."

"I regard antibiotic resistance as the single greatest extant threat to the survival of our species. We all worry about war, nuclear proliferation global warning, tropical deforestation, as well we should. But killer superbugs are killing hundreds of thousands of people every year - and the problem is getting worse. Attacking antibiotic resistant bacteria by inhibiting metabolic pathways - the method being pursued by Pyro - could be one of the most promising ways to achieve this urgent goal", said Mark J. Plotkin, Ph.D., ethnobotanist and co-author of the book, The Killers Within- The Deadly Rise of Drug Resistant Bacteria. "The Killers Within- The Deadly Rise of Drug Resistant Bacteria is a must read for everyone. It is a riveting account of the issues we face if we do not replenish our dwindling arsenal of antibiotics. A simple bacterial infection can end up costing people the loss of limbs or life," commented Mr. Schechter.

Antibiotics are currently used to treat a wide range of bacterial and fungal infections, ranging from minor to life threatening infections. Broad spectrum antibiotics treat a variety of gram-positive and gram-negative bacteria, protist, yeast, and fungal organisms, while mild spectrum antibiotics only cover limited types of bacterial, protist, yeast, and fungal organisms and are useful for curing infections with known bacterial, protist, yeast, and fungal strains. The mechanism of action for most antibiotics is the inhibition of bacterial cell wall completion, or DNA or protein synthesis. Pyro's patent describes a method, for identifying compounds useful for such antibiotic therapy and the treatment of microorganism infections by inhibiting enzymes involved in essential metabolic pathways. Pyro has realized that these distinctions can be used to develop a method for the rational design of drugs, specifically of antibiotics. Identifying metabolic pathways that are unique and essential to pathogenic microorganisms can be used as a method to develop novel therapeutics against these pathogenic species without causing harm to the mammals.

Identification of potential new antibiotics has traditionally been accomplished by screening compounds against cultures of the microorganisms of interest. Such screening procedures may test candidate compounds selected because of their structural similarity to known antibiotics or because of other experimental observations that suggest possible activity. But in either event, this type of screening often times requires many cumbersome experiments in order to identify potential candidate compounds. A more rational approach to drug design and development would more quickly focus on candidate compounds that affect critical targets of the pathogenic microorganism of interest. In other words, instead of blindly screening compounds for possible activity, a rational approach would first identity targets, that if properly inhibited, would adversely affect the viability or infectivity of pathogenic microbes.

The present invention provides a rational drug design approach that more quickly and efficiently focuses drug screening on specific identified targets which are critical and important to viability and infectivity of pathogenic microorganisms. The method of the invention, therefore, comprises:

a) identifying a metabolic pathway in a pathogenic microorganism essential to its viability or infectivity;

b) identifying an enzyme in the pathway that is not present in mammals;

c) confirming that the enzyme is a valid target for affecting the pathogen's viability or infectivity; and

d) screening to identify a compound that inhibits the enzyme.

Pyro has identified one or more enzymes in essential metabolic pathways that are required for the viability of pathogenic microorganisms, but which are absent in mammals, specifically, humans. Since these pathways are important for pathogen viability, inhibiting one or more of them can significantly decrease the viability of the particular pathogen, leading ultimately to its death.

Pyro has already identified a number of important pathogenic bacteria, protist, yeast, and fungal microorganisms in which an essential pathway is required for viability, including but not limited to Yersinia pestis (bubonic plague) , Pseudomonas aeruginosa (urinary tract and other infections; sepsis), Neisseria meningitidis (meningitis), Helicobacter pylori (stomach ulcers; gastritis), Chlamydia trachomatis (urethritis; proctitis); infertility, Chlamydia pneumoniae (pneumonia), Streptococcus pneumoniae (pmeumonia; upper respiratory infection; ear ache), Haemophilus influenzae (influenza), Mycobacterium leprae (leprosy), Mycobacterium tuberculosis (tuberculosis), Vibrio cholerae (cholera), Staphylococcus aureus (nosocomial, skin and other infections), Giardia lamblia (giardiasis; intestinalis), Entamoeba histolytica (dysentery), Trichomonas vaginalis (trichomoniasis), Leishmania donovani (leishmaniasis), Trypannosome cruzi (Chagas Disease), Candida albicans (oral and genital infections), and Falciparum plasmodium (malaria).

"Pyro's mission is clear and concise," commented Mr. Schechter. "Our goal is to develop a new class of antibiotics, and Pyro's portfolio of drug target patents forms the basis of these potential new antibiotics. Our first issued United States patent No. 6955890, is the foundation of our patent portfolio."

About Pyro Pharmaceuticals

Pyro Pharmaceuticals, Inc. is developing therapeutics against multi-drug resistant infectious microorganisms or "Super Bugs." Pyro's focus is on diseases in which antibiotic resistance has become a significant issue. Pyro's plan is to develop a new class of antibiotics for a wide variety of pathogenic microorganisms, especially those that have exhibited multiple drug resistance. Antibiotic resistance is a growing public health concern worldwide. According to the Center for Disease Control ("CDC"), antibiotic drug resistance has significantly increased mortality rates, making infectious disease the third largest cause of death in the United States. Drug resistance has also increased the cost of health care delivery. Examples of the types of bacteria that have become resistant to antibiotics include the species that cause skin infections, meningitis, sexually transmitted diseases, respiratory tract infections such as pneumonia and tuberculosis, and multi-drug resistant Staphylococcus aureus (MRSA).

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Fero Industries, Inc. (the Company) to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov under "Search for Company Filings."

For more information, visit Pyro's website at www.pyropharmaceuticals.com or contact Michael Irving at Interactive Resources Group, Inc. at 1-866-998-9669 Ext.150